ICUI Quote, Financials, Valuation and Earnings

Merit Medical Systems has a net margin of -3.78% compared to ICU Medical's net margin of 7.87%. ICU Medical's return on equity of -5.75% beat Merit Medical Systems's return on equity of 9.36%.

ICU Medical has a consensus price target of $190.00, signalling upside risk potential of 29.19%. On the other hand Merit Medical Systems has an analysts' consensus of $118.20 which suggests that it could grow by 16.26%. Given that ICU Medical has higher upside potential than Merit Medical Systems, analysts believe ICU Medical is more attractive than Merit Medical Systems.

ICU Medical has a beta of 0.733, which suggesting that the stock is 26.693% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.607%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $629.8M, which are larger than Merit Medical Systems quarterly revenues of $355.2M. ICU Medical's net income of -$23.8M is lower than Merit Medical Systems's net income of $27.9M. Notably, ICU Medical's price-to-earnings ratio is -- while Merit Medical Systems's PE ratio is 50.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.51x versus 4.45x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of -3.78% compared to ICU Medical's net margin of -20.22%. ICU Medical's return on equity of -5.75% beat Repligen's return on equity of -1.29%.

ICU Medical has a consensus price target of $190.00, signalling upside risk potential of 29.19%. On the other hand Repligen has an analysts' consensus of $194.07 which suggests that it could grow by 38.63%. Given that Repligen has higher upside potential than ICU Medical, analysts believe Repligen is more attractive than ICU Medical.

ICU Medical has a beta of 0.733, which suggesting that the stock is 26.693% less volatile than S&P 500. In comparison Repligen has a beta of 0.950, suggesting its less volatile than the S&P 500 by 5.001%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $629.8M, which are larger than Repligen quarterly revenues of $167.5M. ICU Medical's net income of -$23.8M is higher than Repligen's net income of -$33.9M. Notably, ICU Medical's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.51x versus 12.41x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -3.78% compared to ICU Medical's net margin of 26.88%. ICU Medical's return on equity of -5.75% beat ResMed's return on equity of 25.56%.

ICU Medical has a consensus price target of $190.00, signalling upside risk potential of 29.19%. On the other hand ResMed has an analysts' consensus of $270.09 which suggests that it could grow by 22.94%. Given that ICU Medical has higher upside potential than ResMed, analysts believe ICU Medical is more attractive than ResMed.

ICU Medical has a beta of 0.733, which suggesting that the stock is 26.693% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. ICU Medical pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ICU Medical quarterly revenues are $629.8M, which are smaller than ResMed quarterly revenues of $1.3B. ICU Medical's net income of -$23.8M is lower than ResMed's net income of $344.6M. Notably, ICU Medical's price-to-earnings ratio is -- while ResMed's PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.51x versus 6.58x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -3.78% compared to ICU Medical's net margin of -10.04%. ICU Medical's return on equity of -5.75% beat Xtant Medical Holdings's return on equity of -35.34%.

ICU Medical has a consensus price target of $190.00, signalling upside risk potential of 29.19%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 224.07%. Given that Xtant Medical Holdings has higher upside potential than ICU Medical, analysts believe Xtant Medical Holdings is more attractive than ICU Medical.

ICU Medical has a beta of 0.733, which suggesting that the stock is 26.693% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $629.8M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. ICU Medical's net income of -$23.8M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, ICU Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.51x versus 0.62x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.